CellEDIT - CRISPR-Edited MCF7 Cell Line
We provide you with a custom and high-quality engineered MCF7 cell line to support your research.
We’ll engineer your MCF7 cell line, so you can speed up your experiment.
The MCF7 cell line was derived from a human breast adenocarcinoma. This cell line is widely used in biomedical research and industrial applications. This is due to its well-characterized nature and responsiveness to hormones.
MCF7 Cell Line Information
Organism
Human
Tissue Type
Breast - Mammary Gland
Cell Type
Epithelial
Disease
Adenocarcinoma
Karyotype
Polyploid
Donor Information
Age
69
Gender
Female
Ethnicity
Unknown
MCF7 Cell Line Applications
Cancer Research: MCF7 cells are extensively used to study breast cancer biology, including tumor growth, metastasis, and the molecular mechanisms underlying cancer progression.
Drug Screening and Development: These cells are a standard model for testing the efficacy and toxicity of new anticancer drugs, particularly those targeting breast cancer.
Hormone Research: MCF7 cells are hormone-responsive, making them ideal for studying the effects of estrogen and other hormones on cell proliferation, differentiation, and gene expression.
Genetic Studies: Researchers use MCF7 cells to investigate the roles of specific genes and genetic pathways in cancer development and treatment resistance.
Signal Transduction Studies: These cells help elucidate the signaling pathways involved in cancer cell growth and survival, in particular, pathways regulated by hormones and growth factors.
Related Case Studies
Further your research output by leveraging our expertise. Engineered MCF7 cell lines contribute to significant advancements in understanding breast cancer and developing new therapeutic strategies. With the CellEDIT workflow and within 10 weeks, we can generate custom CRISPR-edited MCF7 cell lines through direct intra-nuclear injection, suited for your project needs.
![CellEDIT Engineered MCF7 Cell Line - Cytosurge CellEDIT Engineered MCF7 Cell Line - Cytosurge](https://cdn.cytosurge.com/web/image/311508-d7088fcf/icon-cell-70x70.png)
Efficient on
Hard-to-transfect cells
![CellEDIT Engineered MCF7 Cell Line - Cytosurge CellEDIT Engineered MCF7 Cell Line - Cytosurge](https://cdn.cytosurge.com/web/image/442268-c774bd61/icon-scissors-70x70.png)
Vector-free
direct intra-nuclear delivery
![CellEDIT Engineered MCF7 Cell Line - Cytosurge CellEDIT Engineered MCF7 Cell Line - Cytosurge](https://cdn.cytosurge.com/web/image/442267-b7d9756b/icon-bullseye-70x70.png)
Minimized Off-Target
Immortalized Cells
Discover how the CellEDIT workflow was used to generate 5 monoclonal HPRT knockouts in C2C12 cell line through direct intra-nuclear injection of only 51 cells.
Cancer Cells
Explore how
the CellEDIT workflow was used to produce
3 monoclonal HPRT1 knockouts in SK-MES-1 cell, a notoriously hard-to-transfect cell line.
Available Edits using CellEDIT Engineered Cells
Knockout
Save time in the lab by empowering your research with CellEDIT. Confidently streamline your drug discovery workflow and investigate gene function with effective CRISPR knockouts.
Multiplex Editing
At CellEDIT,
we provide you with multiplexed cell lines in 10 weeks. The efficiency and gentleness of our vector-free editing through intra-nuclear delivery, makes it an ideal system to perform multiplex gene editing in one go.
Related Resources
Educational
Technical
Introduction to CRISPR Knockout Gene Editing with CellEDIT
An Overview of CellEDIT' CRISPR Cell Line Development Services
CellEDIT' CRISPR Cell Line Development Workflow
CellEDIT's Engineered Cell Lines
CRISPR-Engineered U2OS Cell Line
CRISPR-Engineered MDA MB 231 Cell Line
CRISPR-Engineered A549 Cell Line
CRISPR-Edited Hek293 Cell Line
Media & Downloads
On-Demand CellEDIT's CRISPR Cell Line Engineering Webinar
CellEDIT's Application Note n*1 - Introducing the CellEDIT Workflow
CellEDIT's Application Note n*2 - Overcoming the hard-to-transfect cell line hurdle
Open Access Publication featuring CellEDIT: Antony, Justin S., Anabel Migenda Herranz, Tahereh Mohammadian Gol, Susanne Mailand, Paul Monnier, Jennifer Rottenberger, Alicia Roig‐Merino et al. " Accelerated generation of gene-engineered monoclonal CHO cell lines using FluidFM nanoinjection and CRISPR/Cas9" Biotechnology Journal 19, no. 4 (2024): 2300505.